Heart shield? common diabetes drug tested to prevent chemo damage in breast cancer
NCT ID NCT06427226
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether dapagliflozin, a drug used for diabetes, can prevent heart damage caused by the chemotherapy drug doxorubicin in breast cancer patients. Researchers will enroll 46 women with early-stage breast cancer who are about to start chemotherapy. Participants will take dapagliflozin daily during their treatment cycles, and doctors will monitor heart function using echocardiograms and blood tests to see if the drug helps maintain a healthy heart.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dapagliflozin (a diabetes drug repurposed to protect the heart)
What this could lead to
If it works, this could offer a simple way to protect breast cancer patients' hearts during chemotherapy, reducing the risk of long-term heart problems.
What could go wrong
This is a small, early-phase trial with only 46 participants, so results may not apply to everyone. Dapagliflozin may not prevent heart damage, and side effects like dehydration or infection are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Medical Research Institute
RECRUITINGAlexandria, Bab Sharqi, 21526, Egypt
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••